CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0752 (clinicaltrials.gov NCT No: NCT00698009)
Title:Study to Infuse Haploidentical Natural Killer Cells in Patients with Relapsed or Refractory Neuroblastoma
Principal Investigator:Susan S. Kelly
Treatment Agent:Cyclophosphamide; Fludarabine; Interleukin-2; Mesna; Natural Killer Cells
Study Status:Terminated
Study Description:The goal of this clinical research study is to find out if infusing your NK
cells into your relative's body can be done safely for him or her. Researchers
also want to find out if the infused cells will survive after the infusion, and
if the NK cell infusion can help to destroy neuroblastoma cells in the
recipient’s body.

Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation; Pediatrics; Solid Tumors
Phase of Study:Phase II
Treatment Agents:Cyclophosphamide
Fludarabine
Interleukin-2
Mesna
Natural Killer Cells
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Patients will be in the hospital at least one night following NK cell infusion
and first dose of IL-2.
Supported By:N/A
Return Visit:Once discharged, patients will return to MDACC at least two times per week
until neutrophil recovery; then once a month for three months; then once every
three months until one year post infusion.
Home Care:Subcutaneous IL-2 three times a week for nine doses.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Susan S. Kelly
Dept:Pediatrics
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults